Yves Massicotte

Jan 15, 2025 | outsourcedpharma.com | Louis Garguilo |Yadnyesh Patel |Vaibhav Patel |Yves Massicotte

Transitioning Your Product from Phase 1 to Phase 2 Clinical StudiesTransitioning oral solid dosage (OSD) forms from Phase 1 to Phase 2 clinical studies demands effective strategies and solutions to overcome formulation and development challenges. This whitepaper explores practical techniques to refine formulations, manage Phase 1 outcomes, and optimize timelines.

Oct 23, 2024 | outsourcedpharma.com | Louis Garguilo |Tim Sandle |Yves Massicotte

Webinar: Peptide-Based Therapeutics: Developing and Scaling Through Innovative TechnologiesPeptide-based therapeutics are thriving, prompting advances in their manufacturing. This webinar features Cambrex experts discussing liquid-phase peptide synthesis (LPPS), peptide crystallization, and impurity analysis methods. Key topics include LPPS vs.

Sep 3, 2024 | pharmaceuticalonline.com | Chris Ovett |Idbs Hq |Yves Massicotte |Geoff Middleton

Webinar: Client Sustainability Directives- CDMO PerspectivesThis webinar discusses pharmaceutical industry sustainability initiatives from various perspectives of Contract Manufacturing Organizations. You’ll gain an understanding of current directives and metrics, discuss CDMO strategies to overcome the immensity of the tasks to get started, and identify paths forward to address the directives that ensures a positive outcome for the CDMO, its stakeholders, and the world. Click here to learn more.

Jun 28, 2024 | outsourcedpharma.com | Louis Garguilo |David O’Connell |Yves Massicotte

Looking for the best CDMOs in the world? Here’s the full issue of the 2024 CDMO Leadership Awards to help. Full details on all Award winners included for OutsourcedPharma.com readers. A Spy At ModernaJason Kerr of Moderna is a snoop, a spy, and a watcher of all things. More officially, he’s tasked by his employer with monitoring regulatory changes in the environment. “Some do call it regulatory surveillance,” he says, “Some just regulatory monitoring.” Whichever, you might need to hire a Kerr, too.

Jun 21, 2024 | outsourcedpharma.com | Louis Garguilo |Geoff Middleton |Yves Massicotte |Leachables Case Study

An integral FDA touchstone with your CDMOs are drug master files (DMFs). Ben Stevens, Director CMC Policy and Advocacy at GSK, advises readers on how to avoid the ramifications of which from taking you by unpleasant surprise. Design And Function Of GMP Transition SpacesIn pharma/biotech GMP, there are several spaces that function as transition spaces, such as air locks. This deep dive discusses how procedure and arrangement can influence their effectiveness.